Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 2Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Conditions

Breast Neoplasms 176Neoplasms 173Carcinoma, Non-Small-Cell Lung 152Prostatic Neoplasms 108Colorectal Neoplasms 105Lung Neoplasms 91Ovarian Neoplasms 82Neoplasm Metastasis 76Multiple Myeloma 72Pancreatic Neoplasms 70Leukemia, Myeloid, Acute 63Endometrial Neoplasms 49Squamous Cell Carcinoma of Head and Neck 47Stomach Neoplasms 45Melanoma 44Lymphoma 44Glioblastoma 42Carcinoma, Renal Cell 42Recurrence 41Brain Neoplasms 41Urinary Bladder Neoplasms 39Carcinoma, Hepatocellular 39Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Sarcoma 37Glioma 36Lymphoma, Non-Hodgkin 35Hematologic Neoplasms 35Leukemia, Lymphocytic, Chronic, B-Cell 34Esophageal Neoplasms 33Small Cell Lung Carcinoma 31

Interventions

darolutamide 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Bulbo-Spinal Atrophy, X-Linked × 30 days × Clear all
NCT07190300 2026-06-03

TulmiSTAR-02

Novartis

Phase 1/2 Recruiting
181 enrolled

Bulbo-Spinal Atrophy, X-Linked

NCT04708431 2026-05-19

Androgen Receptor, Implications for Health and Wellbeing: Natural History Study of Individuals With Androgen Insensitivity

National Institutes of Health Clinical Center (CC)

Recruiting
650 enrolled

Androgen-Insensitivity Syndrome, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon âš¡